Norman Kimberley, Mustafa Sara Tareq, Cassim Shemana, Mullins Hilde, Clark Penny, Keenan Rawiri, Te Karu Leanne, Murphy Rinki, Paul Ryan, Kenealy Tim, Chepulis Lynne
School of Primary and Allied Health Care, Monash University, Melbourne, Australia.
Medical Research Centre, Te Huataki Waiora School of Health, University of Waikato, Hamilton, New Zealand.
Prim Health Care Res Dev. 2024 Sep 16;25:e34. doi: 10.1017/S1463423624000264.
To explore the views of general practitioners (GPs) and nurses on type 2 diabetes (T2D) management, including the use of recently funded T2D medications in New Zealand (NZ) and their perceived barriers to providing optimal care.
T2D is a significant health concern in NZ, particularly among Māori and Pacific adults. Characterised by prolonged hyperglycaemia, T2D is generally a progressive condition requiring long-term care.
Semi-structured interviews were conducted between July and December 2022 with 21 primary care clinicians (10 GPs and 11 nurses/nurse prescribers) from nine different general practice clinics across the Auckland and Waikato regions of NZ. Framework analysis was conducted to identify common themes in clinicians' perceptions and experiences with T2D management.
Three themes were identified: health-system factors, new medications, and solution-based approaches. Lack of clinician time, healthcare funding, staff shortages, and burn-out were identified as barriers to T2D management under health-system factors. The two newly funded medications, empagliflozin and dulaglutide, were deemed to be a positive change for T2D care in that they improved patient satisfaction and clinical outcomes, but several clinicians were hesitant to prescribe these medications. Participants suggested that additional education and specialist diabetes support would be helpful to inform optimal medication prescribing and that better use of a multi-disciplinary team (clinical and support staff) could support T2D care by reducing workload, addressing cultural gaps in healthcare delivery, and reducing burnout. An improved primary care work environment, including appropriate professional development to support prescribing of new medications and the value of collaboration with a non-regulated workforce, may be required to facilitate optimal T2D management in primary care. Future research should focus on interventions to increase support for both clinical teams and patients while adopting a culturally appropriate approach to increase patient satisfaction and improve health outcomes.
探讨全科医生(GP)和护士对2型糖尿病(T2D)管理的看法,包括在新西兰(NZ)使用近期资助的T2D药物情况以及他们认为在提供最佳护理方面存在的障碍。
T2D是新西兰一个重大的健康问题,在毛利人和太平洋岛民成年人中尤为突出。T2D的特征是长期高血糖,通常是一种需要长期护理的渐进性疾病。
2022年7月至12月期间,对来自新西兰奥克兰和怀卡托地区9家不同全科诊所的21名初级保健临床医生(10名全科医生和11名护士/护士处方医生)进行了半结构化访谈。采用框架分析法确定临床医生对T2D管理的看法和经验中的共同主题。
确定了三个主题:卫生系统因素、新药物和基于解决方案的方法。在卫生系统因素下,临床医生时间不足、医疗保健资金、人员短缺和职业倦怠被确定为T2D管理的障碍。两种新资助的药物恩格列净和度拉鲁肽被认为是T2D护理的积极变化,因为它们提高了患者满意度和临床结果,但一些临床医生对开具这些药物持犹豫态度。参与者建议,额外的教育和糖尿病专科支持将有助于指导最佳药物处方,更好地利用多学科团队(临床和支持人员)可以通过减轻工作量、解决医疗服务中的文化差距和减少职业倦怠来支持T2D护理。可能需要改善初级保健工作环境,包括提供适当的专业发展以支持新药物的处方以及与非正规劳动力合作的价值,以促进初级保健中最佳的T2D管理。未来的研究应侧重于采取文化上适当的方法增加对临床团队和患者的支持,同时提高患者满意度并改善健康结果的干预措施。